Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Februar 2019 05:04 ET | Quelle: Lupin Ltd

Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 1 February 2019: Lupin is pleased to...
08. Januar 2019 00:00 ET | Quelle: Lupin Neurosciences Ltd

Lupin Limited: Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 8 January 2019: Lupin is pleased to announce that the...
19. Oktober 2018 07:44 ET | Quelle: Lupin Neurosciences Ltd

Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, October 19, 2018: Lupin Neurosciences, a...